TY - JOUR
T1 - Prevalence and persistence of antibodies to herpes viruses, Chlamydia pneumoniae and Helicobater pylori in Alaskan Eskimos
T2 - The GOCADAN
AU - Zhu, Jianhui
AU - Davidson, M.
AU - Leinonen, M.
AU - Saikku, P.
AU - Gaydos, C. A.
AU - Canos, D. A.
AU - Gutman, K. A.
AU - Howard, B. V.
AU - Epstein, S. E.
N1 - Funding Information:
The GOCADAN study is supported by the National Institutes of Health (grant RO1 HL41642). The authors thank all those involved in sample and data collections. We are grateful to H. E. Resnick for her constant support in statistical analysis, and specifically thank C. Wenger, Y. Famogun and F. Abdullah for their technical assistance.
PY - 2006/2
Y1 - 2006/2
N2 - The prevalence and persistence of antibodies against cytomegalovirus (CMV), herpes simplex virus types 1 (HSV1) and 2 (HSV2), Helicobacter pylori and Chlamydia pneumoniae were determined in Alaskan Eskimos. The study included 610 individuals (mean age 43 ± 15 years; 45% males) participating in the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study. Archived serum samples and those collected during the GOCADAN study were analysed for antibodies against the above pathogens by ELISA. The current prevalence of antibody seropositivity was 94% to CMV, 90% to HSV1, 38% to HSV2, 80% to H. pylori, and 42% to C. pneumoniae. The persistence of antibodies (in both archived and current samples) against CMV, HSV1 and H. pylori was high (83%, 84% and 67%, respectively) compared with those against HSV2 (26%) and C. pneumoniae (29%). Moreover, the seroconversion rates to these organisms were low. Most individuals acquired CMV, HSV1 and H. pylori antibodies by the age of 24 years (94%, 90% and 72%, respectively), and >50% carried HSV2 and C. pneumoniae antibodies by the age of 45 years. There were gender differences in antibody seropositivity rates. Over 70% of individuals had antibodies to at least three of the five pathogens tested. The study demonstrated the high prevalence and lifelong persistence of multiple antibodies, suggesting chronic infections among Alaskan Eskimos.
AB - The prevalence and persistence of antibodies against cytomegalovirus (CMV), herpes simplex virus types 1 (HSV1) and 2 (HSV2), Helicobacter pylori and Chlamydia pneumoniae were determined in Alaskan Eskimos. The study included 610 individuals (mean age 43 ± 15 years; 45% males) participating in the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study. Archived serum samples and those collected during the GOCADAN study were analysed for antibodies against the above pathogens by ELISA. The current prevalence of antibody seropositivity was 94% to CMV, 90% to HSV1, 38% to HSV2, 80% to H. pylori, and 42% to C. pneumoniae. The persistence of antibodies (in both archived and current samples) against CMV, HSV1 and H. pylori was high (83%, 84% and 67%, respectively) compared with those against HSV2 (26%) and C. pneumoniae (29%). Moreover, the seroconversion rates to these organisms were low. Most individuals acquired CMV, HSV1 and H. pylori antibodies by the age of 24 years (94%, 90% and 72%, respectively), and >50% carried HSV2 and C. pneumoniae antibodies by the age of 45 years. There were gender differences in antibody seropositivity rates. Over 70% of individuals had antibodies to at least three of the five pathogens tested. The study demonstrated the high prevalence and lifelong persistence of multiple antibodies, suggesting chronic infections among Alaskan Eskimos.
KW - Alaskan Eskimos
KW - Antibodies
KW - Chlamydia pneumoniae
KW - Cytomegalovirus
KW - Helicobacter pylori
KW - Herpes simplex virus
UR - http://www.scopus.com/inward/record.url?scp=33644908817&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644908817&partnerID=8YFLogxK
U2 - 10.1111/j.1469-0691.2005.01319.x
DO - 10.1111/j.1469-0691.2005.01319.x
M3 - Article
C2 - 16441448
AN - SCOPUS:33644908817
SN - 1198-743X
VL - 12
SP - 118
EP - 122
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - 2
ER -